Pure Global
NCT06361186

Proximod Pharmacokinetics In Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects.
Longevity Inc.·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Rheumatoid Arthritis
Drug/Device/Intervention
Proximod
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Longevity Inc.
Location
Changchun, China
Timeline & enrollment
Phase
Phase 1
Start date
Sep 14, 2017
End date
Jun 22, 2021
Enrollment
134 participants
Primary outcome

Peak plasma concentration (Cmax),Time to peak plasma concentration (Tmax),The lowest plasma concentration (Cmin),Half-life (t1/2),Number of adverse events and number of participants with adverse events

Summary

The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and
 pharmacodynamics of Proximod in healthy subjects. The main questions it arms to answer are:
 
 1. to evaluate the safety and tolerance of Proximod in healthy subjects after single or
 repeated doses.
 
 2. to learn the pharmacodynamics of Proximod in healthy subjects after single or repeated
 doses.
 
 3. to evaluation of the effect of food on the pharmacokinetics of Proximod in healthy
 subjects Participants will receive test tablets or placebo at the indicated date and
 collect blood samples.

ICD-10 classifications
Rheumatoid arthritis, unspecifiedOther rheumatoid arthritisOther specified rheumatoid arthritisRheumatoid arthritis with involvement of other organs and systemsSeronegative rheumatoid arthritis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06361186
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06361186 through Pure Global AI's free database. This Phase 1 trial is sponsored by Longevity Inc. and is currently Completed. The study focuses on Rheumatoid Arthritis. Target enrollment is 134 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.